Healthcare / Medical DistributionSão Paulo
$1.34
-0.01 (-0.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-151.1M · quality 32.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$423M
P/E
22.3x
↑EV/EBITDA
3.8x
↓ROE
0.9%
↑Gross Margin
14.4%
↓Debt/Equity
2.00
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.8%
FCF CAGR
-22.9%
FCF margin
1.1%
FCF / Net income
6.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.57B · net income $18.2M · FCF $125.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.57B | $11.57B | $11.58B | $11.08B | $8.75B |
| Net Income | $18.2M | $18.2M | $-1.42B | $359.9M | $259.7M |
| EBITDA | $966.9M | $966.9M | $-791.0M | $1.06B | $721.1M |
| EPS | 0.06 | 0.06 | -4.46 | 1.20 | 0.92 |
| Gross Margin | 14.4% | 14.4% | 11.3% | 15.7% | 16.0% |
| Operating Margin | 4.8% | 4.8% | -5.2% | 5.7% | 5.8% |
| Net Margin | 0.2% | 0.2% | -12.2% | 3.2% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.00 | 2.00 | 2.18 | 1.04 | 1.53 |
| Current Ratio | 1.33 | 1.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $125.3M | $125.3M | $-151.1M | $-1.20B | $273.4M |
| Returns | |||||
| ROE | 0.9% | 0.9% | -73.5% | 10.9% | 11.4% |
| Valuation | |||||
| P/E | 22.33 | 22.33 | — | 10.76 | 16.95 |
| EV/EBITDA | 3.85 | 3.85 | — | 6.44 | 9.48 |
| P/B | 0.22 | 0.22 | 0.34 | 1.18 | 1.93 |
| Growth & Yield | |||||
| Revenue Growth | -0.1% | -0.1% | 4.5% | 26.7% | — |
| EPS Growth | 101.3% | 101.3% | -471.5% | 31.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.2%
EPS terminal req.
$0.12
Spread vs growth
74.1%
5Y implied EPS CAGR
20.0%
EPS terminal req.
$0.14
Spread vs growth
81.3%
10Y implied EPS CAGR
14.9%
EPS terminal req.
$0.23
Spread vs growth
86.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.46 → 0.06
Residual
-0.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.